Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy.
about
Radioimmunotherapy of human synovial sarcoma using a monoclonal antibody against FZD10First-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces?Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancerDual fatty acid synthase and HER2 signaling blockade shows marked antitumor activity against breast cancer models resistant to anti-HER2 drugsFrom bench to bedside: What do we know about hormone receptor-positive and human epidermal growth factor receptor 2-positive breast cancer?Phosphodiesterase type 5 inhibitors increase Herceptin transport and treatment efficacy in mouse metastatic brain tumor modelst-Darpp Promotes Enhanced EGFR Activation and New Drug Synergies in Her2-Positive Breast Cancer CellsDrug development against metastasis-related genes and their pathways: A rationale for cancer therapySTAT3 mediates resistance of CD44(+)CD24(-/low) breast cancer stem cells to tamoxifen in vitro.The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway.Dual HER2 blockade: preclinical and clinical dataMonoclonal antibody against the ectodomain of E-cadherin (DECMA-1) suppresses breast carcinogenesis: involvement of the HER/PI3K/Akt/mTOR and IAP pathwaysImaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancerEGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in HER2/ER-positive breast cancer cells but functions synergistically with endocrine therapy.Tracking of multimodal therapeutic nanocomplexes targeting breast cancer in vivo.An integrated bioinformatics approach identifies elevated cyclin E2 expression and E2F activity as distinct features of tamoxifen resistant breast tumors.Ron receptor tyrosine kinase activation confers resistance to tamoxifen in breast cancer cell linesA phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer.Krüppel-like factor 4 induces apoptosis and inhibits tumorigenic progression in SK-BR-3 breast cancer cells.HER-3 targeting alters the dimerization pattern of ErbB protein family members in breast carcinomas.Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenograftsCardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancerGefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study.Grape polyphenols inhibit Akt/mammalian target of rapamycin signaling and potentiate the effects of gefitinib in breast cancer.Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.Insulin-like growth factor-dependent proliferation and survival of triple-negative breast cancer cells: implications for therapy.Trimodal glioblastoma treatment consisting of concurrent radiotherapy, temozolomide, and the novel TGF-β receptor I kinase inhibitor LY2109761.Loss of B-cell translocation gene 2 expression in estrogen receptor-positive breast cancer predicts tamoxifen resistance.Risk of severe diarrhea with dual anti-HER2 therapies: a meta-analysis.ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancerLapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancerβ1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib.HER2: biology, detection, and clinical implicationsA critical role for HER3 in HER2-amplified and non-amplified breast cancers: function of a kinase-dead RTK.Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancerInhibiting PI3K reduces mammary tumor growth and induces hyperglycemia in a mouse model of insulin resistance and hyperinsulinemia.Expression and purification of HER2 extracellular domain proteins in Schneider2 insect cells.Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation.Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy.Systematic drug screening reveals specific vulnerabilities and co-resistance patterns in endocrine-resistant breast cancer
P2860
Q24313293-B18CFC5C-1B6F-4726-BE73-200F9AD3F83FQ26746081-D2F52FB0-417D-449F-8ADD-B1FD34D2BDBDQ26785612-AA22FFCE-2659-492F-9652-C81B53FBEFF3Q27303674-3BFD6233-B57B-4F59-A8CB-F5B445C39657Q28084982-E81C971B-CEDD-46E1-9C4E-88B813D167A0Q28473716-FA250CB7-EB01-4D20-9467-3803EFBF4A73Q28545954-A3303C72-983D-4766-A495-CC3E07F404F8Q29010479-9E6462D1-EAE5-43EE-A4FA-6E71D3C0169CQ30420135-A2E6F5C4-FDB7-4734-B052-3D678CB3091DQ30425478-3CBEB23B-0FCB-42AE-AAF0-E87918DEEFE2Q30941327-DB44E4E9-9C70-4A9C-9F33-91C4E5A05BBBQ33584432-B942539D-DB12-4500-99FD-08460CC940BFQ33641143-62924348-0E7B-4EE7-B43C-FC25B724337EQ33794923-0B318FA5-ABA0-481E-BA75-B2427563090DQ33874414-828BF30C-125E-413D-BE54-268F3AF24E34Q33971409-F0C285A1-B3CF-4C56-8BD9-8C0F8CD523B3Q34041328-5205B581-0487-4C9E-AEA8-7ECAF5102114Q34077853-30267DF1-2AA3-4C03-AF71-4B91764573B2Q34469953-974FC3E4-736A-43F0-87A6-550F32295706Q34506951-44462E11-9E98-479A-8F69-5816283E5A0BQ34694605-6900C583-BCC8-4FF3-BEBC-B1883FC612FEQ34775370-4B5A62AF-B920-4E15-B425-190C0230C16EQ34781067-D1A174BF-CFDA-40EF-BBAC-1E511B4C7969Q34855692-AD23C61E-1586-40D0-9985-FC83BB39E535Q35000243-EA9A008A-24CE-4C9E-BCED-420031F82D01Q35042972-D75ACF96-323B-400A-AA8B-4970C652AA5AQ35042985-C81D3E27-9153-457B-9984-A255027E992FQ35051765-18D282C3-B329-4526-BB66-6BF8513B944AQ35077315-FA6E32D6-A03F-45AA-A1DF-88AED578340CQ35479617-40546763-EA19-4C7C-9755-52E38CA551E2Q35583927-081EEEF4-75BB-455A-8D19-FD80D18C5883Q35608736-9216BF7F-BE87-43E8-9D2A-A4C9581D932CQ35622862-423054AC-559E-4A45-A932-1B419D43C2E1Q35682599-903520BE-5A74-4661-A45E-55CF7F99B126Q35742383-B30127F5-BD9C-47A0-BED6-5BB11762F835Q35745395-0087019B-9FA0-472B-9BD0-5C4026B1462AQ35771539-28C89A58-0335-4BFE-A57F-A09F9FB43C3FQ35889621-B6D19271-A81D-4FF0-AEF1-6B4D3B8D3410Q36021424-4B345C41-2FCA-4D5E-BC4D-B36F9A434E49Q36067934-9A5B226E-F6B1-4589-9B75-F1928909610E
P2860
Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Treatment of human epidermal g ...... ltiagent HER-targeted therapy.
@en
type
label
Treatment of human epidermal g ...... ltiagent HER-targeted therapy.
@en
prefLabel
Treatment of human epidermal g ...... ltiagent HER-targeted therapy.
@en
P2093
P2860
P356
P1476
Treatment of human epidermal g ...... ltiagent HER-targeted therapy.
@en
P2093
C Kent Osborne
Carolina Gutierrez
Grazia Arpino
Heidi Weiss
Lavina Bharwani
Mothaffar Rimawi
Rachel Schiff
Sabino De Placido
Suleiman Massarweh
P2860
P304
P356
10.1093/JNCI/DJK151
P407
P577
2007-05-01T00:00:00Z